📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
Sygnature Discovery named as Finalist in 2019 OBN Award Best CRO
Sygnature Discovery is pleased to announce that we are a finalist in the OBN Awards…
News
Sygnature Discovery moves US base to Kendall Square
Sygnature Discovery’s US office has moved, our new location is 245 First Street in Cambridge,…
Blog
Augmented Reality: the future of drug discovery collaboration?
Experience the future of drug discovery collaboration with augmented reality (AR). Sygnature Discovery's Computational Chemistry department is transforming molecular visualisation using Microsoft HoloLens. Explore virtual molecules, collaborate in 3D, and revolutionize design meetings. Embrace the power of AR in drug discovery.
Blog
Sygnature Discovery Turns 15 – Celebrate With Us!
Join us in celebrating our remarkable growth and success in the drug discovery space. From a small lab to the UK's largest independent CRO!
News
Sygnature Discovery wins Outstanding Achievement Award
Sygnature Discovery have been named as the winner of the Outstanding Achievement award at the…
News
2019 recap!
2019 has been another busy and successful year for us at Sygnature Discovery. During the…
News
Récapitulatif de 2019 !
L’année 2019 a été une année chargée et fructueuse pour Sygnature Discovery. Au cours de…
Blog
We need new anti-viral medicines more than ever
It is estimated that the animal kingdom harbours more than 1.5m viruses. Humans are increasingly…
Blog
The benefits of speed and choice; DMPK on its own or in combination with synthesis services
Speed is of the essence in pharma R&D, and companies are always looking to get…
Blog
Effective Strategies for Successful Hit Identification in Drug Discovery
Discover effective hit identification strategies in drug discovery at Sygnature Discovery. Explore knowledge-based hit generation, High Throughput Screening (HTS), large database virtual screening, and fragment-based screening. Our expert scientists can guide your project to success.
Journal Papers
High Throughput Screening: Methods, Techniques and Applications (Chapter 7)
Discover High Throughput Screening (HTS) in drug discovery. Expert insights, methods, and applications for successful hit identification. Essential knowledge for researchers in today's and future laboratories.
Blog
Hit Discovery at Sygnature Discovery
HTS for drug discovery; how to enable successful hit finding High throughput screening (HTS) is…
Blog
Reducing clinical risk with earlier drug discovery toxicology
We undertake a detailed risk assessment for every experiment we perform in the lab, but…
News
Sygnature provides equipment to Government’s COVID-19 testing efforts
Sygnature Discovery is actively bolstering the Government’s COVID-19 testing strategy through a significant contribution: the…
Blog
Future of Protein Degradation Beyond PROTACs
Beyond PROTACs – what’s next in target protein degradation? Significant research effort is…
Blog
RNA-based drug discovery, new assays? new possibilities?
The revolutionary field of Ribonucleic acid (RNA) based drug discovery could lead to life-changing medicines…
News
Sygnature Discovery Enhances SPR Capacity with Expansion
Sygnature Discovery have installed a fourth Biacore surface plasmon resonance (SPR) system at our BioCity,…
News
Sygnature expands capabilities with acquisition of Alderley Oncology
Great news, at Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the…
News
Sygnature assists New York Medical College in the fight against Covid-19
We are very proud to be supporting Professor Sachin Gupte, a pharmacologist at the…
News
Sygnature Discovery boosts senior management team with appointment of Dr Paul Overton
We have strengthened our senior management team with the appointment of Dr Paul Overton as…
Blog
Could multimodal pharmacotherapies help us defeat obesity?
In recent decades, obesity has become a global epidemic. Dr David Loczenski, Business Development Manager…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch